Compugen Signs $500M Agreement With Bayer

Israeli biopharmaceutical company Compugen, which develops antibody-based cancer treatments, has entered into a commercialization agreement with American pharmaceutical company Bayer HealthCare.

The two companies will work on researching, developing and commercializing Compugen’s treatments, based on immune checkpoint regulators discovered by the company. The deal is worth $500 million.